3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Radiotherapy
3
Cisplatin
3
Radiation
2
pegfilgrastim
1
hydrated silica gel-based toothpaste
1
glucarpidase
1
angiotensin I (1-7)
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Selenomethionine
1
Neck Dissection
1
Methotrexate
1
Lidocaine
1
Leucovorin
1
Ketamine
1
Granulocyte Colony-Stimulating Factor
1
Glutamine
1
Fluorouracil
1
Filgrastim
1
Fibroblast Growth Factor 7
1
Everolimus
1
Docetaxel
1
Diphenhydramine
1
Curcumin
1
Amifostine
1
Acupuncture Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Mucositis
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled